Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients
The aim of the present study is to investigate the synergic role of <sup>68</sup>Ga-PSMA PET/MRI and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in prostate cancer (PCa) staging. We present pilot data on twenty-two patients with biopsy-proven PCa that underwent <sup>68</sup>...
Guardado en:
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4ecd835d579a4984862cb5adb3863929 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:4ecd835d579a4984862cb5adb3863929 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:4ecd835d579a4984862cb5adb38639292021-11-25T17:21:21ZPreliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients10.3390/diagnostics111120682075-4418https://doaj.org/article/4ecd835d579a4984862cb5adb38639292021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4418/11/11/2068https://doaj.org/toc/2075-4418The aim of the present study is to investigate the synergic role of <sup>68</sup>Ga-PSMA PET/MRI and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in prostate cancer (PCa) staging. We present pilot data on twenty-two patients with biopsy-proven PCa that underwent <sup>68</sup>Ga-PSMA PET/MRI for staging purposes, with 19/22 also undergoing <sup>68</sup>Gaa-DOTA-RM2 PET/MRI. TNM classification based on image findings was performed and quantitative imaging parameters were collected for each scan. Furthermore, twelve patients underwent radical prostatectomy with the availability of histological data that were used as the gold standard to validate intraprostatic findings. A DICE score between regions of interest manually segmented on the primary tumour on <sup>68</sup>Ga-PSMA PET, <sup>68</sup>Ga-DOTA-RM2 PET and on T2 MRI was computed. All imaging modalities detected the primary PCa in 18/19 patients, with <sup>68</sup>Ga-DOTA-RM2 PET not detecting any lesion in 1/19 patients. In the remaining patients, <sup>68</sup>Ga-PSMA and MRI were concordant. Seven patients presented seminal vesicles involvement on MRI, with two of these being also detected by <sup>68</sup>Ga-PSMA, and <sup>68</sup>Ga-DOTA-RM2 PET being negative. Regarding extraprostatic disease, <sup>68</sup>Ga-PSMA PET, <sup>68</sup>Ga-DOTA-RM2 PET and MRI resulted positive in seven, four and five patients at lymph-nodal level, respectively, and at a bone level in three, zero and one patients, respectively. These preliminary results suggest the potential complementary role of <sup>68</sup>Ga-PSMA PET, <sup>68</sup>Ga-DOTA-RM2 PET and MRI in PCa characterization during the staging phase.Paola MapelliSamuele GhezzoAna Maria Samanes GajateErik PrezaGiorgio BrembillaVito CucchiaraNaghia AhmedCarolina BezziLuca PresottoValentino BettinardiAnnarita SaviPatrizia MagnaniRaffaele MenichiniAngela ColivaIlaria NeriEttore Di GaetaLuigi GianolliMassimo FreschiAlberto BrigantiFrancesco De CobelliPaola ScifoMaria PicchioMDPI AGarticlehybrid imagingPET/MRIPSMARM2prostate cancermultimodal imagingMedicine (General)R5-920ENDiagnostics, Vol 11, Iss 2068, p 2068 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
hybrid imaging PET/MRI PSMA RM2 prostate cancer multimodal imaging Medicine (General) R5-920 |
spellingShingle |
hybrid imaging PET/MRI PSMA RM2 prostate cancer multimodal imaging Medicine (General) R5-920 Paola Mapelli Samuele Ghezzo Ana Maria Samanes Gajate Erik Preza Giorgio Brembilla Vito Cucchiara Naghia Ahmed Carolina Bezzi Luca Presotto Valentino Bettinardi Annarita Savi Patrizia Magnani Raffaele Menichini Angela Coliva Ilaria Neri Ettore Di Gaeta Luigi Gianolli Massimo Freschi Alberto Briganti Francesco De Cobelli Paola Scifo Maria Picchio Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients |
description |
The aim of the present study is to investigate the synergic role of <sup>68</sup>Ga-PSMA PET/MRI and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in prostate cancer (PCa) staging. We present pilot data on twenty-two patients with biopsy-proven PCa that underwent <sup>68</sup>Ga-PSMA PET/MRI for staging purposes, with 19/22 also undergoing <sup>68</sup>Gaa-DOTA-RM2 PET/MRI. TNM classification based on image findings was performed and quantitative imaging parameters were collected for each scan. Furthermore, twelve patients underwent radical prostatectomy with the availability of histological data that were used as the gold standard to validate intraprostatic findings. A DICE score between regions of interest manually segmented on the primary tumour on <sup>68</sup>Ga-PSMA PET, <sup>68</sup>Ga-DOTA-RM2 PET and on T2 MRI was computed. All imaging modalities detected the primary PCa in 18/19 patients, with <sup>68</sup>Ga-DOTA-RM2 PET not detecting any lesion in 1/19 patients. In the remaining patients, <sup>68</sup>Ga-PSMA and MRI were concordant. Seven patients presented seminal vesicles involvement on MRI, with two of these being also detected by <sup>68</sup>Ga-PSMA, and <sup>68</sup>Ga-DOTA-RM2 PET being negative. Regarding extraprostatic disease, <sup>68</sup>Ga-PSMA PET, <sup>68</sup>Ga-DOTA-RM2 PET and MRI resulted positive in seven, four and five patients at lymph-nodal level, respectively, and at a bone level in three, zero and one patients, respectively. These preliminary results suggest the potential complementary role of <sup>68</sup>Ga-PSMA PET, <sup>68</sup>Ga-DOTA-RM2 PET and MRI in PCa characterization during the staging phase. |
format |
article |
author |
Paola Mapelli Samuele Ghezzo Ana Maria Samanes Gajate Erik Preza Giorgio Brembilla Vito Cucchiara Naghia Ahmed Carolina Bezzi Luca Presotto Valentino Bettinardi Annarita Savi Patrizia Magnani Raffaele Menichini Angela Coliva Ilaria Neri Ettore Di Gaeta Luigi Gianolli Massimo Freschi Alberto Briganti Francesco De Cobelli Paola Scifo Maria Picchio |
author_facet |
Paola Mapelli Samuele Ghezzo Ana Maria Samanes Gajate Erik Preza Giorgio Brembilla Vito Cucchiara Naghia Ahmed Carolina Bezzi Luca Presotto Valentino Bettinardi Annarita Savi Patrizia Magnani Raffaele Menichini Angela Coliva Ilaria Neri Ettore Di Gaeta Luigi Gianolli Massimo Freschi Alberto Briganti Francesco De Cobelli Paola Scifo Maria Picchio |
author_sort |
Paola Mapelli |
title |
Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients |
title_short |
Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients |
title_full |
Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients |
title_fullStr |
Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients |
title_full_unstemmed |
Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of <sup>68</sup>Ga-PSMA and <sup>68</sup>Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients |
title_sort |
preliminary results of an ongoing prospective clinical trial on the use of <sup>68</sup>ga-psma and <sup>68</sup>ga-dota-rm2 pet/mri in staging of high-risk prostate cancer patients |
publisher |
MDPI AG |
publishDate |
2021 |
url |
https://doaj.org/article/4ecd835d579a4984862cb5adb3863929 |
work_keys_str_mv |
AT paolamapelli preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT samueleghezzo preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT anamariasamanesgajate preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT erikpreza preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT giorgiobrembilla preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT vitocucchiara preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT naghiaahmed preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT carolinabezzi preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT lucapresotto preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT valentinobettinardi preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT annaritasavi preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT patriziamagnani preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT raffaelemenichini preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT angelacoliva preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT ilarianeri preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT ettoredigaeta preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT luigigianolli preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT massimofreschi preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT albertobriganti preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT francescodecobelli preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT paolascifo preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients AT mariapicchio preliminaryresultsofanongoingprospectiveclinicaltrialontheuseofsup68supgapsmaandsup68supgadotarm2petmriinstagingofhighriskprostatecancerpatients |
_version_ |
1718412470211575808 |